KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $767.1 million.

  • Pacific Biosciences Of California's Total Liabilities fell 2305.7% to $767.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767.1 million, marking a year-over-year decrease of 2305.7%. This contributed to the annual value of $753.9 million for FY2024, which is 2784.09% down from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Total Liabilities is $767.1 million, which was down 2305.7% from $764.0 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Total Liabilities peaked at $1.2 billion during Q4 2021, and registered a low of $753.9 million during Q4 2024.
  • For the 5-year period, Pacific Biosciences Of California's Total Liabilities averaged around $1.0 billion, with its median value being $1.0 billion (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 144924.0% in 2021, then plummeted by 2784.09% in 2024.
  • Over the past 5 years, Pacific Biosciences Of California's Total Liabilities (Quarter) stood at $1.2 billion in 2021, then dropped by 0.97% to $1.2 billion in 2022, then dropped by 13.24% to $1.0 billion in 2023, then fell by 27.84% to $753.9 million in 2024, then rose by 1.75% to $767.1 million in 2025.
  • Its Total Liabilities stands at $767.1 million for Q3 2025, versus $764.0 million for Q2 2025 and $769.2 million for Q1 2025.